BioSpace News Archive

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, announced today the preliminary results of its substantial issuer bid (the “Offer”) to repurchase for cancellation up to 4.0 million of its common shares (the “Common Shares”) at a set purchase price of $6.50 per Common Share for a total purchase price of up to $26.0 million in cash.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has dosed the first patient in AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company’s second generation investigational RNA interference (RNAi) therapeutic being developed as a treatment for the rare genetic liver disease associated with alpha-1 antitrypsin deficiency (AATD)

Heska Corporation (NASDAQ: HSKA - News; “Heska” or the “Company”), a provider of advanced veterinary diagnostic and specialty products, announced that Kevin Wilson, Heska’s President & Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference

NewLink Genetics Corporation (NASDAQ:NLNK) announced today that, after priority review, the FDA has granted approval of ERVEBO®, or Zaire Ebola virus vaccine V920 (rVSV∆G-ZEBOV-GP), as confirmed by our partner, Merck (NYSE:MRK), known as MSD outside the US and Canada.

Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics delivering evidence-based therapeutic interventions to patients, announced today that Alfred Farrington, II has joined the Company as acting Chief Information Officer, reporting to Chief Executive Officer Ben Kaplan, effective today.

The CDMO segment of the world’s leading biotech company GenScript announced that GenScript’s plasmid and virus facility was put into operation on December 18, 2019.

BioUtah applauds congressional action to permanently repeal the 2.3% excise tax on the sale of medical devices, first enacted as part of the Affordable Care Act in 2010.

Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, announced its Chief Executive Officer Bill Athenson will present at Biotech Showcase 2020 to be held January 13-15, 2020 at the Hilton San Francisco Union Square.

Demonstrates Evoke® ECAP-Controlled Closed-Loop SCS Provides Statistically Superior Pain Relief Compared to Open-Loop SCS

Accelerated Approval of Daiichi Sankyo and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) based on the pivotal DESTINY-Breast01 trial that showed clinically meaningful and durable responses